The Curious Case Of Human Gene Patents

by Pepper Hamilton LLP

Originally Published on - May 22, 2013.

The U.S. Supreme Court heard oral arguments last month in the matter of Association for Molecular Pathology v. Myriad Genetics, a curious case that does not bode well for America’s biotechnology industry and could overturn 30 years of U.S. patent policy.

This case has been orchestrated by the American Civil Liberties Union (ACLU), representing a coalition of public interest petitioners. Ostensibly, the ACLU wants to drive down the cost of health care in the United States by eliminating patent protection for so-called “gene patents” held by Myriad Genetics. The ACLU would like us to believe that gene patents are fundamentally wrong – and that they are blocking the development of personalized medicine.

At issue is whether the composition-of-matter claims in patents owned by Myriad are eligible for patent protection. These patents are based on the discovery that mutations of two gene sequences – BRCA1 and BRCA2 – increase some women’s susceptibility to breast or ovarian cancer. The inventors filed for patents and Myriad raised and spent more than $500 million to develop genetic screening tests.

As we await the Supreme Court’s decision, which is expected next month, here are four curiosities to be aware of in the case.

Curiosity #1: The Obama Administration’s Position on Gene Patents

The Obama administration has decided to weigh in largely on the side of the ACLU, despite a longstanding policy of the U.S. Patent and Trademark Office (USPTO) in favor of gene patents.

In fact, the USPTO has granted thousands of patents on DNA sequences – like those in the BRCA mutations – since 1982. USPTO guidelines state that compositions of matter derived from genetic material “can be the basis for a patent” where the particular gene (a molecule) is “isolated from its natural state and processed through purifying steps that separate the gene from other molecules naturally associated with it.”

The Obama administration has taken a slightly different position than the ACLU, saying that some of Myriad’s claims are patentable while others are not. At the oral arguments, Solicitor General Donald Verrilli argued that isolated DNA should be off limits because it is a product of nature, while some of Myriad’s claims to “complimentary DNA” (cDNA) are permissible because cDNA can be synthesized. The logic of this compromise position is deeply flawed because isolated DNA can also be synthesized. Moreover, cDNA is simply a condensed version of genetic DNA; it can just as well be considered “more isolated DNA.”

Even if the Court adopts the Solicitor General’s compromise position, it still opens a Pandora’s Box of questions about the limits of this new doctrine. Gene patents are part of a larger class of biotechnology patents – perhaps more than 100,000 – that have likewise enjoyed long-standing USPTO and judicial approval. A brief submitted by the industry group BIO identifies numerous other biotech inventions that could be ensnared by prohibiting the patenting of isolated biological materials: stem cells, vaccines (derived from live viruses), antibiotics (isolated from bacteria), insulin, human growth hormone and a slew of industrially or therapeutically useful enzymes.

Curiosity #2: The Questions Raised by the Supreme Court During Oral Arguments

The questions raised by several members of the Court during oral arguments suggest that the distinction between isolated DNA and isolated cDNA was not foremost in their minds. Justice Sotomayor, for example, posed a hypothetical question about baking cookies from natural materials and asked whether she could get a patent on salt or flour. Justice Kagan asked whether the first person who found the liver should have gotten a patent on it. Justice Breyer was preoccupied with the possibility that isolated BRCA genes could actually exist in nature through some freak happenstance.

It is hard to make any predictions based on the Supreme Court’s reductio ad absurdum approach to patent law issues. However, for the past several years, the Supreme Court has been trying to rein in the scope of patents. Judicial activism has resulted in whole classes of inventions being declared ineligible for patent protection.

The Court’s 2012 decision in Mayo v. Prometheus sent shockwaves through the intellectual property community by invalidating patents on medical diagnostic methods, invoking a rarely used judicial doctrine to bar patents that essentially claim an abstract idea, law of nature or inhibit the use of natural laws in making further discoveries.

The Myriad case threatens to hack away yet another class of inventions from patent protection. A decision in favor of the petitioners in this case could bar future patents on a host of biological materials and invalidate thousands of already issued patents.

Curiosity #3: The ACLU’s Argument that Gene Patents Increase Medical Costs

Even if the Court decides that some or all of Myriad’s claims are ineligible for patent protection, it is not at all clear whether the social policy objective of reducing health care costs would be achieved.

Many gene patents are based on discoveries from the 1990s, and the 20 years of patent protection for these inventions will soon expire. (Even if they survive this litigation, Myriad’s patents will expire by late 2015.) Thus, the post-patent marketplace – rather than a victory for the ACLU – will largely determine the cost of genetic testing in the future.

Curiosity #4: Barring Gene Patents Contradicts the Government’s Stance on Free Trade Negotiations

In negotiating NAFTA, as well as in talks currently underway with countries like Japan for a Trans-Pacific Partnership (TPP), the U.S. Commerce Department insisted that other countries broadly define patentable subject matter and provide patent protection for diagnostic methods and isolated biological materials – at the same time the Supreme Court unravels patent protection for these categories of inventions at home.

All in all, a loss for Myriad may have serious unintended consequences for other inventions derived from biological materials and create a disincentive for future investments in biotechnology research.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Pepper Hamilton LLP | Attorney Advertising

Written by:

Pepper Hamilton LLP

Pepper Hamilton LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.